Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Pliant Therapeutics (PLRX) Shares Outstanding (Diluted Average) (2019 - 2025)

Pliant Therapeutics (PLRX) has disclosed Shares Outstanding (Diluted Average) for 7 consecutive years, with $61.4 million as the latest value for Q4 2025.

  • On a quarterly basis, Shares Outstanding (Diluted Average) rose 1.37% to $61.4 million in Q4 2025 year-over-year; TTM through Dec 2025 was $61.4 million, a 1.37% increase, with the full-year FY2025 number at $61.4 million, up 1.37% from a year prior.
  • Shares Outstanding (Diluted Average) was $61.4 million for Q4 2025 at Pliant Therapeutics, roughly flat from $61.3 million in the prior quarter.
  • In the past five years, Shares Outstanding (Diluted Average) ranged from a high of $61.4 million in Q2 2025 to a low of $35.6 million in Q1 2021.
  • A 5-year average of $50.7 million and a median of $58.0 million in 2023 define the central range for Shares Outstanding (Diluted Average).
  • Peak YoY movement for Shares Outstanding (Diluted Average): skyrocketed 1778.37% in 2021, then rose 1.19% in 2022.
  • Pliant Therapeutics' Shares Outstanding (Diluted Average) stood at $35.8 million in 2021, then increased by 17.21% to $42.0 million in 2022, then skyrocketed by 39.75% to $58.7 million in 2023, then rose by 3.1% to $60.5 million in 2024, then rose by 1.37% to $61.4 million in 2025.
  • Per Business Quant, the three most recent readings for PLRX's Shares Outstanding (Diluted Average) are $61.4 million (Q4 2025), $61.3 million (Q3 2025), and $61.4 million (Q2 2025).